GAMMA Investing LLC Has $7.25 Million Position in Certara, Inc. (NASDAQ:CERT)

GAMMA Investing LLC increased its holdings in Certara, Inc. (NASDAQ:CERT - Free Report) by 751.8% in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 71,726 shares of the company's stock after purchasing an additional 63,305 shares during the period. GAMMA Investing LLC's holdings in Certara were worth $7,245,000 at the end of the most recent quarter.

Other hedge funds have also recently added to or reduced their stakes in the company. Blue Trust Inc. grew its stake in shares of Certara by 20.9% during the fourth quarter. Blue Trust Inc. now owns 4,747 shares of the company's stock valued at $56,000 after purchasing an additional 822 shares during the last quarter. The Manufacturers Life Insurance Company grew its stake in shares of Certara by 3.6% during the fourth quarter. The Manufacturers Life Insurance Company now owns 23,720 shares of the company's stock valued at $253,000 after purchasing an additional 823 shares during the last quarter. Wells Fargo & Company MN grew its stake in shares of Certara by 48.4% during the fourth quarter. Wells Fargo & Company MN now owns 3,208 shares of the company's stock valued at $34,000 after purchasing an additional 1,047 shares during the last quarter. Bank of Montreal Can grew its stake in shares of Certara by 9.1% during the fourth quarter. Bank of Montreal Can now owns 19,943 shares of the company's stock valued at $212,000 after purchasing an additional 1,670 shares during the last quarter. Finally, Versant Capital Management Inc grew its stake in shares of Certara by 218.8% during the first quarter. Versant Capital Management Inc now owns 2,719 shares of the company's stock valued at $27,000 after purchasing an additional 1,866 shares during the last quarter. Institutional investors and hedge funds own 73.96% of the company's stock.

Certara Stock Performance

Shares of CERT stock opened at $11.76 on Monday. The company has a market capitalization of $1.91 billion, a price-to-earnings ratio of -58.80, a PEG ratio of 9.29 and a beta of 1.44. The company has a debt-to-equity ratio of 0.28, a quick ratio of 2.86 and a current ratio of 2.86. The company has a 50-day simple moving average of $12.02 and a 200 day simple moving average of $11.86. Certara, Inc. has a 52 week low of $8.64 and a 52 week high of $16.93.

Certara (NASDAQ:CERT - Get Free Report) last posted its quarterly earnings data on Monday, May 5th. The company reported $0.14 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.10 by $0.04. The firm had revenue of $106.00 million during the quarter, compared to the consensus estimate of $104.44 million. Certara had a negative net margin of 8.34% and a positive return on equity of 3.43%. The business's revenue for the quarter was up 9.7% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.10 EPS. On average, sell-side analysts predict that Certara, Inc. will post 0.28 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on the stock. JMP Securities reaffirmed a "market perform" rating on shares of Certara in a research note on Tuesday, May 6th. Robert W. Baird raised their price objective on shares of Certara from $9.00 to $13.00 and gave the company a "neutral" rating in a research note on Friday, April 11th. KeyCorp raised their price objective on shares of Certara from $15.00 to $18.00 and gave the company an "overweight" rating in a research note on Wednesday, April 16th. William Blair reaffirmed a "market perform" rating on shares of Certara in a research note on Thursday, February 27th. Finally, Barclays raised shares of Certara from an "equal weight" rating to an "overweight" rating and raised their price objective for the company from $11.00 to $14.00 in a research note on Thursday, May 8th. Three equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $15.67.

About Certara

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.

Want to see what other hedge funds are holding CERT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Certara, Inc. (NASDAQ:CERT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.